Metastatic or recurrent cervical cancer/treatment

被引：0
作者：
Kurtz, Jean-Emmanuel [1 ]
D'Hondt, Veronique [2 ]
Lecuru, Fabrice [3 ]
Lhomme, Catherine [4 ]
机构：
[1] Hop Univ Strasbourg, Serv Oncol & Hematol, 1 Ave Moliere, F-67098 Strasbourg, France
[2] Inst Reg Canc Montpellier ICM, Dept Oncol Med, 208 Rue Apothicaires, F-34298 Monptellier 5, France
[3] HEGP, Serv Chirurg Cancerol Gynecol & Sein, 20 Rue Leblanc, F-75908 Paris 15, France
[4] Gustave Roussy, Dept Oncol Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, France
来源：
BULLETIN DU CANCER | 2017年 / 104卷
关键词：
Cervical cancer; Recurrent disease; Metastases; Treatment; GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-III; CANCER; TRIAL; PACLITAXEL; CISPLATIN; OUTCOMES; BEVACIZUMAB;
D O I：
10.1016/S0007-4551(17)30161-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The prognosis of metastatic or recurrent cervical cancer remains dismal. The poor chemosensitivity of this tumor- is an issue, especially in case of recurrence in irradiated fields. Still, chemotherapy has shown some efficacy, and mostly consists in platinum-based doublets. The addition of bevacizumab to chemotherapy has been recently validated. However, most of these patients present with complex clinical situations and the treatment strategy has to be discussed in multidisciplinary tumor boards.
引用
收藏
页码：S39 / S42
页数：4
相关论文
共 14 条
  • [1] Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial
    Bakitas, Marie A.
    Tosteson, Tor D.
    Li, Zhigang
    Lyons, Kathleen D.
    Hull, Jay G.
    Li, Zhongze
    Dionne-Odom, J. Nicholas
    Frost, Jennifer
    Dragnev, Konstantin H.
    Hegel, Mark T.
    Azuero, Andres
    Ahles, Tim A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1438 - 1445
  • [2] Current imaging strategies for the evaluation of uterine cervical cancer
    Bourgioti, Charis
    Chatoupis, Konstantinos
    Moulopoulos, Lia Angela
    [J]. WORLD JOURNAL OF RADIOLOGY, 2016, 8 (04): : 342 - 354
  • [3] Duport N., 2014, Bulletin Epidemiologique Hebdomadaire, P220
  • [4] Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505
    Kitagawa, Ryo
    Katsumata, Noriyuki
    Shibata, Taro
    Kamura, Toshiharu
    Kasamatsu, Takahiro
    Nakanishi, Toru
    Nishimura, Sadako
    Ushijima, Kimio
    Takano, Masashi
    Satoh, Toyomi
    Yoshikawa, Hiroyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (19) : 2129 - U151
  • [5] Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A gynecologic oncology group study
    Long, HJ
    Bundy, BN
    Grendys, EC
    Benda, JA
    McMeekin, DS
    Sorosky, J
    Miller, DS
    Eaton, LA
    Fiorica, JV
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) : 4626 - 4633
  • [6] Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: A Gynecologic Oncology Group study
    McQuellon, Richard P.
    Thaler, Howard T.
    Cella, David
    Moore, David H.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 101 (02) : 296 - 304
  • [7] Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
    Monk, Bradley J.
    Sill, Michael W.
    McMeekin, D. Scott
    Cohn, David E.
    Ramondetta, Lois M.
    Boardman, Cecelia H.
    Benda, Jo
    Cella, David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4649 - 4655
  • [8] Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study
    Moore, DH
    Blessing, JA
    McQuellon, RP
    Thaler, HT
    Cella, D
    Benda, J
    Miller, DS
    Olt, G
    King, S
    Boggess, JF
    Rocereto, TF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3113 - 3119
  • [9] Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)
    Penson, Richard T.
    Huang, Helen Q.
    Wenzel, Lari B.
    Monk, Bradley J.
    Stockman, Sharon
    Long, Harry J., III
    Ramondetta, Lois M.
    Landrum, Lisa M.
    Oaknin, Ana
    Reid, Thomas J. A.
    Leitao, Mario M.
    Method, Michael
    Michael, Helen
    Tewari, Krishnansu S.
    [J]. LANCET ONCOLOGY, 2015, 16 (03) : 301 - 311
  • [10] Scatchard K, 2012, COCHRANE DB SYST REV, P10
12